Literature DB >> 15618580

Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status.

M A Spruit1, M J Thomeer, R Gosselink, T Troosters, A Kasran, A J T Debrock, M G Demedts, M Decramer.   

Abstract

BACKGROUND: Skeletal muscle weakness is assumed to be present in patients with sarcoidosis but has never been reported in a consecutive group of patients. Moreover, its relationship with previously observed exercise intolerance and reduced health status has never been studied in these patients.
METHODS: Pulmonary function, skeletal and respiratory muscle forces, peak and functional exercise capacity, health status, and the circulating levels of inflammatory and anabolic markers were determined in 25 patients with sarcoidosis who complained of fatigue (15 men) and in 21 healthy subjects (13 men).
RESULTS: Patients with sarcoidosis had lower respiratory and skeletal muscle forces, reduced exercise capacity and health status, higher anxiety and depression scores, and higher circulating levels of tumour necrosis factor-alpha than healthy subjects (all p< or =0.01). Its soluble receptor p75 tended to be higher (p=0.04). Circulating levels of interleukin (IL)-6, IL-8, insulin-like growth factor I and its binding protein 3 were not significantly different between the two groups. Skeletal muscle weakness was related to exercise intolerance, depression, and reduced health status in patients with sarcoidosis, irrespective of age, sex, body weight and height (p< or =0.05). Quadriceps peak torque was inversely related to fatigue but not to the circulating levels of inflammatory or anabolic markers. The mean daily dose of corticosteroids received in the 6 month period before testing was related to quadriceps peak torque only in patients who received oral corticosteroids.
CONCLUSION: Skeletal muscle weakness occurs in patients with sarcoidosis who complain of fatigue and is associated with reduced health status and exercise intolerance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618580      PMCID: PMC1747159          DOI: 10.1136/thx.2004.022244

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  53 in total

1.  Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis.

Authors:  K E Sietsema; M Kraft; L Ginzton; O P Sharma
Journal:  Chest       Date:  1992-09       Impact factor: 9.410

2.  Dysphoria and sarcoidosis.

Authors:  R A DeRemee
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1998-03       Impact factor: 0.670

3.  A measure of quality of life for clinical trials in chronic lung disease.

Authors:  G H Guyatt; L B Berman; M Townsend; S O Pugsley; L W Chambers
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

4.  Sarcoidosis: the value of exercise testing.

Authors:  A E Medinger; S Khouri; P K Rohatgi
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

5.  High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients.

Authors:  M Cicoira; A P Bolger; W Doehner; M Rauchhaus; C Davos; R Sharma; F O Al-Nasser; A J Coats; S D Anker
Journal:  Cytokine       Date:  2001-07-21       Impact factor: 3.861

6.  Resistance versus endurance training in patients with COPD and peripheral muscle weakness.

Authors:  M A Spruit; R Gosselink; T Troosters; K De Paepe; M Decramer
Journal:  Eur Respir J       Date:  2002-06       Impact factor: 16.671

7.  Impaired exercise response in sarcoid patients with normal pulmonary functio.

Authors:  Alain Delobbe; Hélène Perrault; Jocelyne Maitre; Sophie Robin; Claude Hossein-Foucher; Benoit Wallaert; Bernard Aguilaniu
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2002-06       Impact factor: 0.670

8.  Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I.

Authors:  M A Spruit; R Gosselink; T Troosters; A Kasran; G Gayan-Ramirez; P Bogaerts; R Bouillon; M Decramer
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

9.  Clinical correlates of granulomas in muscle.

Authors:  T Mozaffar; G Lopate; A Pestronk
Journal:  J Neurol       Date:  1998-08       Impact factor: 4.849

10.  Corticosteroids and skeletal muscle function in cystic fibrosis.

Authors:  Sinead C Barry; Charles G Gallagher
Journal:  J Appl Physiol (1985)       Date:  2003-06-13
View more
  26 in total

1.  Quality of life in sarcoidosis: comparing the impact of ocular and non-ocular involvement of the disease.

Authors:  Leorey N Saligan; Grace Levy-Clarke; Tongtong Wu; Lisa J Faia; Keith Wroblewski; Steven Yeh; Robert B Nussenblatt; H Nida Sen
Journal:  Ophthalmic Epidemiol       Date:  2010-08       Impact factor: 1.648

Review 2.  Respiratory and lower limb muscle function in interstitial lung disease.

Authors:  Marios Panagiotou; Vlasis Polychronopoulos; Charlie Strange
Journal:  Chron Respir Dis       Date:  2016-01-14       Impact factor: 2.444

Review 3.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 4.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

5.  Benefits of Physical Training in Sarcoidosis.

Authors:  Bert Strookappe; Jeff Swigris; Jolanda De Vries; Marjon Elfferich; Ton Knevel; Marjolein Drent
Journal:  Lung       Date:  2015-08-19       Impact factor: 2.584

6.  The six-minute walk test in patients with pulmonary sarcoidosis.

Authors:  Esam H Alhamad
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

7.  Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients.

Authors:  Esam H Alhamad; Majdy M Idrees; Mohammed O Alanezi; Ahmad A Alboukai; Shaffi Ahmad Shaik
Journal:  Ann Thorac Med       Date:  2010-04       Impact factor: 2.219

8.  Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis.

Authors:  Esam H Alhamad; Shaffi Ahmad Shaik; Majdy M Idrees; Mohammed O Alanezi; Arthur C Isnani
Journal:  BMC Pulm Med       Date:  2010-08-09       Impact factor: 3.317

9.  The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension.

Authors:  Rubina M Khair; Chisom Nwaneri; Rachel L Damico; Todd Kolb; Paul M Hassoun; Stephen C Mathai
Journal:  Ann Am Thorac Soc       Date:  2016-06

Review 10.  Pulmonary hypertension caused by sarcoidosis.

Authors:  Enrique Diaz-Guzman; Carol Farver; Joseph Parambil; Daniel A Culver
Journal:  Clin Chest Med       Date:  2008-09       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.